Supplement Stack for Energy: NMN, Magnesium, and What Else the Evidence Supports

A well-designed supplement stack for energy addresses the problem at the cellular level rather than the neurotransmitter level. Stimulants — caffeine, ephedrine, racetams — produce subjective energy by increasing sympathetic output or blocking adenosine receptors. This works acutely but does not address the underlying causes of chronic low energy: declining mitochondrial efficiency, reduced NAD+ availability, poor sleep quality from cortisol dysregulation, and depleted cofactors like magnesium. An evidence-based energy stack targets those root mechanisms and produces more durable results without the crash-and-cycle pattern of stimulant dependence. This article builds that stack layer by layer, from foundational deficiency correction to targeted functional support.

The Evidence Base

Human trial evidence for subjective energy specifically is harder to evaluate than for discrete biomarkers like blood pressure or serum NAD+ levels, because energy is multifactorial and difficult to isolate in controlled designs. That said, several compounds have strong mechanistic and clinical evidence for improving the biological substrates of sustained energy: mitochondrial respiratory efficiency, cellular NAD+ availability, cortisol regulation, and sleep architecture quality. The stack below is built from compounds with the strongest published evidence to those providing essential supporting infrastructure.

Key reference points: Yoshino et al. (2021, Science) demonstrated that NMN supplementation improved skeletal muscle insulin sensitivity — a functional measure of mitochondrial metabolic efficiency — in prediabetic postmenopausal women at 250 mg/day. Igarashi et al. (2022, npj Aging) showed improved walking speed and grip strength in healthy older men after 12 weeks of NMN, indirectly reflecting improved cellular ATP production. Gomes et al. (2013, Cell) established the core aging mechanism — NAD+ decline disrupts nuclear-mitochondrial communication and reduces electron transport chain efficiency — underpinning the entire NMN energy rationale. Liao et al. (2021, J Int Soc Sports Nutr) directly demonstrated VO2 max improvements in runners, a measure tightly coupled to mitochondrial oxidative capacity.

Why Energy Is a Mitochondrial Problem

Most cases of chronic low energy in adults without identifiable medical causes — hypothyroidism, anemia, sleep apnea — trace to mitochondrial inefficiency rather than fuel shortage. The mitochondria continuously generate ATP from glucose, fatty acids, and amino acids via the electron transport chain, but the efficiency of this process declines measurably with age. NAD+ is the central variable. As the primary electron carrier at complexes I and III of the respiratory chain, NAD+ concentration directly determines the rate at which mitochondria can convert metabolic fuel to usable ATP. NAD+ levels decline by an estimated 40–60% from age 20 to 60 in most tissues (Gomes et al., 2013), and this decline in electron carrier availability is reflected as reduced ATP output — subjectively experienced as lower baseline energy, slower recovery from exertion, and increased cognitive fatigue under demand.

Effective energy stacks address different physiological levers—here is how the key ingredients compare:

Magnesium is the second-tier variable with outsized practical importance. ATP is biologically active only as the Mg-ATP complex — free magnesium ions must bind to ATP before cellular enzymes can use it. Magnesium deficiency therefore functionally reduces energy availability even when mitochondrial ATP production is running normally. An estimated 50–70% of Western adults do not meet the dietary reference intake for magnesium, making this a widespread and straightforwardly correctable contributor to energy problems. The interaction between NMN and mitochondria — specifically how NAD+ availability affects electron transport chain throughput — is explored in detail in that companion article.

Layer 1: NAD+ Repletion — NMN

NMN is the highest-evidence option for restoring NAD+ pools in adults experiencing age-related decline. Multiple human RCTs confirm that oral NMN raises blood NAD+ levels dose-dependently and produces downstream functional improvements in metabolic and physical performance. The dose-response curve appears meaningful between 250 mg and 1,000 mg per day, with diminishing marginal returns above 500 mg in most available data. Niu et al. (2023, Nutrients) demonstrated favorable shifts in NAD+ metabolites and gut microbiota composition with short-term NMN supplementation in a pre-aging cohort.

Timing matters for NMN. NAMPT — the rate-limiting enzyme in the NAD+ salvage pathway — follows a circadian expression pattern, with activity peaking in the morning hours. Morning NMN supplementation aligns exogenous NAD+ precursor delivery with this natural synthesis peak. Taking NMN fasted or with a light meal reduces bacterial deamidation in the gut, potentially improving net NAD+ conversion efficiency. Bio:sudo NMN 1000mg provides a full 1,000 mg NMN dose per serving with third-party COA documentation, appropriate for the foundational layer of this stack. Starting at 500 mg and assessing response before progressing to 1,000 mg is a reasonable approach.

Layer 2: Magnesium for ATP Function

Magnesium glycinate is the preferred form for systemic energy applications. The glycinate chelate is absorbed via amino acid transporters in the small intestinal brush border, providing reliable delivery largely independent of gastric acid levels — important in older adults and anyone taking acid-reducing medications. Once intracellular, magnesium activates over 300 enzymes involved in energy metabolism: ATP synthase itself, hexokinase and phosphoglycerate kinase in glycolysis, isocitrate dehydrogenase and alpha-ketoglutarate dehydrogenase in the citric acid cycle, and multiple mitochondrial membrane transporters. Veronese et al. (2021, Eur J Nutr) demonstrated that magnesium supplementation measurably reduces oxidative stress markers — directly relevant because mitochondrial reactive oxygen species production is a key driver of declining respiratory chain efficiency with age.

For energy applications specifically, magnesium malate offers a mechanistic variation worth considering: malate is a Krebs cycle intermediate (the substrate for fumarase, generating fumarate) that may provide direct TCA cycle substrate support alongside elemental magnesium delivery. The evidence for malate's independent contribution beyond magnesium itself is limited but mechanistically plausible. The practical comparison between forms for different goals is covered in detail in Magnesium Malate vs Glycinate. Standard dosing for energy support: 200–400 mg elemental magnesium daily, taken in the evening to support sleep quality and overnight recovery without interference from potential mild sedation in sensitive individuals.

Layer 3: Cortisol Regulation — Ashwagandha KSM-66

Cortisol is the third primary variable in the energy equation. Acute cortisol rises are energizing — the adrenal stress response raises blood glucose, increases heart rate, and sharpens alertness. Chronic cortisol elevation from sustained psychological stress, disrupted sleep, or HPA axis dysregulation produces the opposite effect: fatigue, cognitive fog, suppressed mitochondrial biogenesis, and accelerated NAD+ depletion through CD38 overactivation. Ashwagandha KSM-66 at 300–600 mg per day has the most consistent human evidence for cortisol reduction among available adaptogens. Chandrasekhar et al. (2012) demonstrated a 27.9% reduction in serum cortisol at 300 mg twice daily over 60 days in a double-blind RCT.

For an energy-focused stack, ashwagandha addresses the demand side of the energy equation — reducing the metabolic cost of chronic stress response and freeing mitochondrial capacity for productive cellular work rather than continuous emergency signaling. Critically, it also improves sleep architecture quality across multiple RCTs, and sleep is the most efficient mechanism for restoring NAD+ levels naturally: NAMPT upregulation and the majority of daily NAD+ synthesis occur during slow-wave sleep. The downstream connection between cortisol elevation, magnesium depletion, and NAD+ drain is explored in How Stress Depletes Your Body, which makes the case for cortisol management as foundational rather than supplementary in any energy protocol.

Layer 4: Supporting Cofactors

Several additional compounds provide supporting infrastructure worth considering. Coenzyme Q10 ubiquinol at 100–200 mg per day is a required component of mitochondrial complexes I, II, and III, and levels decline with age and statin medications. For individuals not on statins with no specific CoQ10 depletion, the energy benefit in healthy adults is modest — but for statin users and those over 55, the rationale is strong. B-complex vitamins, particularly B1 (thiamine), B2 (riboflavin), B3 (niacin), and B5 (pantothenic acid), are essential cofactors in glycolysis and citric acid cycle enzymes. Dietary deficiency is less common than magnesium deficiency in Western populations but should be ruled out in those with high alcohol intake, heavily processed diets, or malabsorptive conditions before attributing fatigue to NAD+ decline.

Iron-deficiency anemia is one of the most common and most consistently overlooked causes of fatigue, particularly in premenopausal women. Checking serum ferritin (target above 50 ng/mL for optimal energy, not just above the lab reference range of 12 ng/mL) before investing in NMN or other mitochondrial supplements is a high-value preliminary step. Iron-deficiency fatigue will not respond to this energy stack. Similarly, thyroid dysfunction and obstructive sleep apnea produce fatigue that is refractory to supplementation and should be excluded clinically before pursuing a supplementation-based approach.

What Not to Include

Several commonly marketed energy supplements have weak or absent evidence for the mechanisms described here. Ginseng has inconsistent human data and significant quality variation between products, making clinical application unreliable. NADH supplements have poorly established oral bioavailability as intact molecules. Alpha-lipoic acid has mechanistic relevance but thin clinical energy evidence. Proprietary energy blends combining multiple compounds at individually sub-clinical doses are marketing constructs, not evidence-based protocols. Caffeine works for acute energy but does not address underlying deficits and disrupts sleep architecture when consumed after early afternoon — which undermines the recovery-dependent NAD+ and magnesium repletion that sleep enables. Including caffeine in a longevity-oriented energy stack is counterproductive except when precisely timed and limited in quantity. For practical guidance on managing post-meal energy crashes specifically — a distinct presentation from general energy deficiency — see Post-Meal Energy Dips: How to Review Your Routine.

Who Benefits Most

The energy stack described here is most relevant for adults over 40 experiencing age-associated energy decline, individuals with chronic psychological stress and disrupted sleep, people with confirmed or probable magnesium deficiency (the majority of Western adults over 40 fall into this category), and those recovering from extended physiological stress such as illness, surgery, or prolonged sleep deprivation. The evidence base for NMN in energy specifically is currently stronger in metabolically compromised older adults than in healthy young adults, though NAD+ augmentation should theoretically benefit anyone with confirmed NAD+ decline regardless of metabolic status. Iru et al. (2020) showed favorable NAD+ metabolite shifts even in healthy middle-aged Japanese men with no specific metabolic risk factors.

Practical Takeaways

• Start with magnesium and sleep quality optimization before layering in NMN — correcting foundational deficiencies consistently produces more reliable results than adding advanced compounds to a deficit-ridden baseline.
• NMN 250–500 mg taken in the morning, fasted or with a light meal, is the evidence-supported starting dose for NAD+ repletion; assess response at 4–8 weeks before increasing to 1,000 mg.
• Magnesium glycinate or malate at 200–400 mg elemental daily supports ATP utilization, activates energy metabolism enzymes, and improves sleep quality for overnight recovery.
• Ashwagandha KSM-66 at 300–600 mg per day targets cortisol-driven fatigue — most effective in individuals with genuine chronic stress and poor sleep rather than those with primarily mitochondrial-decline energy issues.
• Rule out iron deficiency (check serum ferritin, not just hemoglobin), thyroid dysfunction, and obstructive sleep apnea before attributing persistent fatigue to NAD+ decline; these will not respond to this stack.
• CoQ10 ubiquinol at 100–200 mg per day is a reasonable addition for statin users and those over 55; the evidence in younger, healthy, non-statin individuals is less compelling.

Bottom Line

An evidence-based supplement stack for energy targets mitochondrial function, NAD+ availability, and cortisol-sleep regulation — not stimulant-driven output. The core stack is NMN for NAD+ precursor support, magnesium glycinate or malate as an ATP cofactor and enzyme activator, and ashwagandha KSM-66 for cortisol regulation and sleep quality. These three compounds address the three main controllable biological variables in cellular energy production. Magnesium has the broadest evidence base; NMN has the strongest specific NAD+ data; ashwagandha's benefit is most pronounced in genuinely stressed individuals. For circadian timing optimization of this stack, the Morning Routine for Energy article covers practical implementation in detail.

References

1. Yoshino M, et al. “Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.” Science. 2021;372(6547):1224–1229. [Source]
2. Igarashi M, et al. “Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men.” npj Aging. 2022;8(1):5. [Source]
3. Irie J, et al. “Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men.” Endocrine Journal. 2020;67(2):153–160. [Source]
4. Liao B, et al. “Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners.” J Int Soc Sports Nutr. 2021;18(1):54. [Source]
5. Gomes AP, et al. “Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging.” Cell. 2013;155(7):1624–1638. [Source]
6. Niu KM, et al. “The impacts of short-term NMN supplementation on serum metabolism, fecal microbiota, and telomere length in pre-aging phase.” Nutrients. 2023;15(3):755. [Source]